Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?

Bochtler T, Krämer A.

Front Oncol. 2019 May 17;9:402. doi: 10.3389/fonc.2019.00402. eCollection 2019. Review.

2.

In Reply.

Bochtler T.

Dtsch Arztebl Int. 2019 Apr 5;116(14):251. doi: 10.3238/arztebl.2019.0251b. No abstract available.

3.

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Saraceni F, Labopin M, Brecht A, Kröger N, Eder M, Tischer J, Labussière-Wallet H, Einsele H, Beelen D, Bunjes D, Niederwieser D, Bochtler T, Savani BN, Mohty M, Nagler A.

J Hematol Oncol. 2019 Apr 25;12(1):44. doi: 10.1186/s13045-019-0727-4.

4.

Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome.

Bochtler T, Endris V, Leichsenring J, Reiling A, Neumann O, Volckmar AL, Kirchner M, Allgäuer M, Schirmacher P, Krämer A, Stenzinger A.

Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32316. [Epub ahead of print]

PMID:
30963573
5.

Hematological Malignancies in Adults With a Family Predisposition.

Bochtler T, Haag GM, Schott S, Kloor M, Krämer A, Müller-Tidow C.

Dtsch Arztebl Int. 2018 Dec 14;115(50):848-854. doi: 10.3238/arztebl.2018.0848. Review.

6.

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.

Dittrich T, Benner A, Kimmich C, Siepen FAD, Veelken K, Kristen AV, Bochtler T, Katus HA, Müller-Tidow C, Hegenbart U, Schönland SO.

Haematologica. 2019 Jul;104(7):1451-1459. doi: 10.3324/haematol.2018.205336. Epub 2019 Jan 17.

7.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C.

Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12.

PMID:
30442503
8.

Micronucleus formation in human cancer cells is biased by chromosome size.

Bochtler T, Kartal-Kaess M, Granzow M, Hielscher T, Cosenza MR, Herold-Mende C, Jauch A, Krämer A.

Genes Chromosomes Cancer. 2019 Jun;58(6):392-395. doi: 10.1002/gcc.22707. Epub 2019 Jan 17.

PMID:
30411433
9.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO.

Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.

10.

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, Basset M, Müller-Tidow C, Bochtler T, Palladini G, Hegenbart U.

Blood. 2018 Nov 1;132(18):1988-1991. doi: 10.1182/blood-2018-04-845396. Epub 2018 Aug 14. No abstract available.

PMID:
30108065
11.

Enasidenib.

Krämer A, Bochtler T.

Recent Results Cancer Res. 2018;212:187-197. doi: 10.1007/978-3-319-91439-8_9.

PMID:
30069631
12.

Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.

Bochtler T, Endris V, Reiling A, Leichsenring J, Schweiger MR, Klein S, Stögbauer F, Goeppert B, Schirmacher P, Krämer A, Stenzinger A.

J Natl Compr Canc Netw. 2018 Jun;16(6):677-682. doi: 10.6004/jnccn.2018.7012.

PMID:
29891518
13.

Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.

Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Lübbert M, Bug G, Krug U, Bochtler T, Voss F, Taube T, Liu D, Garin-Chesa P, Döhner H.

Br J Haematol. 2019 Mar;184(6):1018-1021. doi: 10.1111/bjh.15204. Epub 2018 Jun 8. No abstract available.

PMID:
29882583
14.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

15.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2018 Jan 9;2(1):1-9. doi: 10.1182/bloodadvances.2017013334.

16.

Diagnosis and management of metastatic neoplasms with unknown primary.

Bochtler T, Löffler H, Krämer A.

Semin Diagn Pathol. 2018 May;35(3):199-206. doi: 10.1053/j.semdp.2017.11.013. Epub 2017 Nov 26. Review.

PMID:
29203116
17.

Mesenchymal stromal cells contribute to quiescence of therapy-resistant leukemic cells in acute myeloid leukemia.

Wang W, Bochtler T, Wuchter P, Manta L, He H, Eckstein V, Ho AD, Lutz C.

Eur J Haematol. 2017 Nov;99(5):392-398. doi: 10.1111/ejh.12934. Epub 2017 Sep 13.

PMID:
28800175
18.

Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia.

Wang W, Stiehl T, Raffel S, Hoang VT, Hoffmann I, Poisa-Beiro L, Saeed BR, Blume R, Manta L, Eckstein V, Bochtler T, Wuchter P, Essers M, Jauch A, Trumpp A, Marciniak-Czochra A, Ho AD, Lutz C.

Haematologica. 2017 Sep;102(9):1567-1577. doi: 10.3324/haematol.2016.163584. Epub 2017 May 26.

19.

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, Ho AD, Hegenbart U, Schönland SO.

Blood. 2017 Aug 3;130(5):632-642. doi: 10.1182/blood-2017-02-767475. Epub 2017 May 26.

20.

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.

Haematologica. 2017 Aug;102(8):1424-1431. doi: 10.3324/haematol.2016.163246. Epub 2017 May 18.

21.

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.

Milani P, Schönland S, Palladini G, Kimmich C, Basset M, Russo F, Foli A, Perlini S, Bochtler T, Ho AD, Merlini G, Hegenbart U.

Amyloid. 2017 Mar;24(sup1):56-57. doi: 10.1080/13506129.2017.1292240. No abstract available.

PMID:
28434298
22.

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.

Granzow M, Hegenbart U, Hinderhofer K, Hose D, Seckinger A, Bochtler T, Hemminki K, Goldschmidt H, Schönland SO, Jauch A.

Haematologica. 2017 Jul;102(7):1281-1290. doi: 10.3324/haematol.2016.160721. Epub 2017 Mar 24.

23.

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Chaturvedi A, Herbst L, Pusch S, Klett L, Goparaju R, Stichel D, Kaulfuss S, Panknin O, Zimmermann K, Toschi L, Neuhaus R, Haegebarth A, Rehwinkel H, Hess-Stumpp H, Bauser M, Bochtler T, Struys EA, Sharma A, Bakkali A, Geffers R, Araujo-Cruz MM, Thol F, Gabdoulline R, Ganser A, Ho AD, von Deimling A, Rippe K, Heuser M, Krämer A.

Leukemia. 2017 Oct;31(10):2020-2028. doi: 10.1038/leu.2017.46. Epub 2017 Jan 31.

24.

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.

Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, Hinderhofer K, Heilig CE, Kramer M, Thiede C, Endris V, Kirchner M, Stenzinger A, Benner A, Bornhäuser M, Ehninger G, Ho AD, Jauch A, Krämer A; Study Alliance Leukemia Investigators.

Blood. 2017 Mar 9;129(10):1333-1342. doi: 10.1182/blood-2016-09-738161. Epub 2017 Jan 24.

25.

Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.

Bochtler T, Fröhling S, Weichert W, Endris V, Thiede C, Hutter B, Hundemer M, Ho AD, Krämer A.

Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001123. doi: 10.1101/mcs.a001123.

26.

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.

Kayser S, Benner A, Thiede C, Martens U, Huber J, Stadtherr P, Janssen JW, Röllig C, Uppenkamp MJ, Bochtler T, Hegenbart U, Ehninger G, Ho AD, Dreger P, Krämer A.

Blood Cancer J. 2016 Jul 29;6(7):e449. doi: 10.1038/bcj.2016.46.

27.

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO.

Blood. 2016 Jul 28;128(4):594-602. doi: 10.1182/blood-2015-10-676361. Epub 2016 Jun 2.

28.

Karyotype complexity and prognosis in acute myeloid leukemia.

Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, Hänel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Krämer A, Röllig C, Schetelig J, Bornhäuser M, Ehninger G.

Blood Cancer J. 2016 Jan 15;6:e386. doi: 10.1038/bcj.2015.114.

29.

Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.

Balss J, Thiede C, Bochtler T, Okun JG, Saadati M, Benner A, Pusch S, Ehninger G, Schaich M, Ho AD, von Deimling A, Krämer A, Heilig CE.

Leukemia. 2016 Apr;30(4):782-8. doi: 10.1038/leu.2015.317. Epub 2015 Nov 19.

PMID:
26582645
30.

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G; Study Alliance Leukemia.

Biol Blood Marrow Transplant. 2016 Mar;22(3):462-9. doi: 10.1016/j.bbmt.2015.10.023. Epub 2015 Nov 10.

31.

Reply to R. Warsame et al.

Bochtler T, Hegenbart U, Kunz C, Benner A, Schönland SO.

J Clin Oncol. 2015 Nov 20;33(33):3976-7. doi: 10.1200/JCO.2015.63.2141. Epub 2015 Aug 31. No abstract available.

PMID:
26324370
32.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO.

J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.

PMID:
25779559
33.

Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.

Bochtler T, Fröhling S, Krämer A.

Leukemia. 2015 Jun;29(6):1243-52. doi: 10.1038/leu.2015.32. Epub 2015 Feb 12. Review.

PMID:
25673237
34.

Normal CYP3A activity during arsenic trioxide therapy.

Siller N, Egerer G, Bochtler T, Hohmann N, Mikus G.

Ann Hematol. 2014 Nov;93(11):1941-2. doi: 10.1007/s00277-014-2076-2. Epub 2014 Apr 16. No abstract available.

PMID:
24737309
35.

Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Middeke JM, Fang M, Cornelissen JJ, Mohr B, Appelbaum FR, Stadler M, Sanz J, Baurmann H, Bug G, Schäfer-Eckart K, Hegenbart U, Bochtler T, Röllig C, Stölzel F, Walter RB, Ehninger G, Bornhäuser M, Löwenberg B, Schetelig J.

Blood. 2014 May 8;123(19):2960-7. doi: 10.1182/blood-2013-12-544957. Epub 2014 Mar 20.

36.

Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.

Radujkovic A, Dietrich S, Bochtler T, Krämer A, Schöning T, Ho AD, Dreger P, Luft T.

Eur J Haematol. 2014 Aug;93(2):112-7. doi: 10.1111/ejh.12308. Epub 2014 Apr 3.

PMID:
24628527
37.

Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.

Bochtler T, Hegenbart U, Kunz C, Benner A, Seckinger A, Dietrich S, Granzow M, Neben K, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO.

Amyloid. 2014 Mar;21(1):9-17. doi: 10.3109/13506129.2013.854766. Epub 2014 Jan 23.

PMID:
24455967
38.

Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia.

Bochtler T, Stölzel F, Heilig CE, Kunz C, Mohr B, Jauch A, Janssen JW, Kramer M, Benner A, Bornhäuser M, Ho AD, Ehninger G, Schaich M, Krämer A.

J Clin Oncol. 2013 Nov 1;31(31):3898-905. doi: 10.1200/JCO.2013.50.7921. Epub 2013 Sep 23.

PMID:
24062393
39.

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.

Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, Lohse P, Röcken C.

Blood. 2012 Jan 12;119(2):488-93. doi: 10.1182/blood-2011-06-358507. Epub 2011 Nov 21.

40.

Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders.

Bochtler T, Kirsch M, Maier B, Bachmann J, Klingmüller U, Anderhub S, Ho AD, Krämer A.

Leukemia. 2012 Apr;26(4):728-35. doi: 10.1038/leu.2011.283. Epub 2011 Oct 21.

PMID:
22015771
41.

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14).

Bochtler T, Hegenbart U, Heiss C, Benner A, Moos M, Seckinger A, Pschowski-Zuck S, Kirn D, Neben K, Bartram CR, Ho AD, Goldschmidt H, Hose D, Jauch A, Schonland SO.

Blood. 2011 Apr 7;117(14):3809-15. doi: 10.1182/blood-2010-02-268987. Epub 2011 Feb 10.

42.

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.

Dietrich S, Schönland SO, Benner A, Bochtler T, Kristen AV, Beimler J, Hund E, Zorn M, Goldschmidt H, Ho AD, Hegenbart U.

Blood. 2010 Jul 29;116(4):522-8. doi: 10.1182/blood-2009-11-253237. Epub 2010 Apr 7.

43.

[Systemic light chain amyloidosis - molecular basis and clinical perspectives].

Schönland SO, Moos M, Bochtler T, Ho AD, Hegenbart U.

Dtsch Med Wochenschr. 2009 Sep;134(39):1949-52. doi: 10.1055/s-0029-1237538. Epub 2009 Sep 16. Review. German. No abstract available.

PMID:
19760558
44.

[Current diagnostic and therapy of light chain amyloidosis].

Schönland SO, Bochtler T, Kristen AV, Ho AD, Hegenbart U.

Pathologe. 2009 May;30(3):205-11. doi: 10.1007/s00292-009-1132-5. Review. German.

PMID:
19343349
45.

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.

Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D, Moos M, Bila J, Bartram CR, Ho AD, Goldschmidt H, Jauch A, Schonland SO.

Blood. 2008 May 1;111(9):4700-5. doi: 10.1182/blood-2007-11-122101. Epub 2008 Feb 27.

46.

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.

Bochtler T, Hegenbart U, Heiss C, Benner A, Cremer F, Volkmann M, Ludwig J, Perz JB, Ho AD, Goldschmidt H, Schonland SO.

Haematologica. 2008 Mar;93(3):459-62. doi: 10.3324/haematol.11687. Epub 2008 Feb 20.

47.

DNA damage-induced accumulation of centrosomal Chk1 contributes to its checkpoint function.

Löffler H, Bochtler T, Fritz B, Tews B, Ho AD, Lukas J, Bartek J, Krämer A.

Cell Cycle. 2007 Oct 15;6(20):2541-8. Epub 2007 Jul 30.

PMID:
17726372
48.

Chronic lymphocytic leukaemia and concomitant relapsing polychondritis: a report on one treatment for the combined manifestation of two diseases.

Bochtler T, Hensel M, Lorenz HM, Ho AD, Mahlknecht U.

Rheumatology (Oxford). 2005 Sep;44(9):1199. Epub 2005 Apr 26. No abstract available.

PMID:
15855184

Supplemental Content

Loading ...
Support Center